Cancer drug could cost NHS £4.7m per year of patient life, says NICE

NICE wants to axe funding for Roche’s daily skin cancer pill, Erivedge, saying in final draft guidance that the NHS could spend almost £4.7 million on the drug to restore a year of good quality life to patients. NICE was assessing Erivedge, which first became available via the CDF in 2013, as a treatment for adults with symptomatic basal cell carcinoma, or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.